… of severe COVID-19. The aim of this systematic review was to describe the rationale for the
use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence …

… with better outcomes in moderate and severe COVID-19 patients with signs of … COVID-19
severity. We provide a practical approach on antithrombotic therapy management for COVID-19 …

… and clinical evidence to support the benefit of the influenza, pneumococcal, and tuberculosis
vaccines in the context of COVID-19 as well as to provide an overview on the COVID-19-…

… In this review, the pathogenesis of COVID-19 as a rationale for anti-IL-6 use will … evidence
of potential benefits, safety monitoring, and ongoing experimental clinical studies in COVID-19 …

… In order to provide a general picture of the current safety profile of JAK inhibitors in COVID-19,
we used the COVID-19 EUA section of the FAERS public dashboard to extract AEs of …

… of COVID-19, despite the lack of high-quality evidence. In this … of azithromycin for treating
COVID-19. Interest in azithromycin … Currently, in vivo reports on azithromycin in COVID-19 are …

… In this focused review, we present the biological and scientific rationale for the use of nebulised
UFH for COVID-19 pneumonia and ARDS in hospitalised patients and make a call for an …

… We have collected evidence from all the current studies we are aware of on SARS-CoV-2 …
-1 and MERS-CoV infection linking severe COVID-19 disease directly with dysfunction of the …

… ~15% 26 of patients with severe COVID-19, so lesser exposure of the … evidence of lack of
direct infection. In summary, at present, the cumulative evidence suggests that AKI in COVID-19 …

… COVID-19 based on current literature evidence. The model was set up by identifying the
molecular pathophysiology related to the COVID-19 … a multiomics approach to COVID-19. This …